Roche's headquarters in Basel, Switzerland (Kyle LaHucik for Endpoints News)
Roche ditches final PhIII for cancer hopeful, reports setback for key drug in $1.4B buyout
Over the past few years, Roche has released news about its AKT inhibitor ipatasertib in drips — most of them negative. The drug yielded mixed data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
